المؤلفون: Zang PD; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California., Chawla NS; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California., Barragan-Carrillo R; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California., Chehrazi-Raffle A; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California., Tripathi A; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California., Pal SK; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California., Dorff TB; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.

المصدر: JAMA oncology [JAMA Oncol] 2024 Apr 01; Vol. 10 (4), pp. 531-532.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/pathology, Male ; Humans ; Biomarkers, Tumor

المؤلفون: Oudard S; Oncology Department, Hopital European Georges-Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Cité, Paris, France.; Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, Paris, France., Ratta R; Oncology Department, Foch Hospital, Suresnes, France., Voog E; Oncology Department, Jean Bernard Center, Le Mans, France., Barthelemy P; Oncology Department, Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Thiery-Vuillemin A; Oncology Department, Centre Hospitalier Universitaire (CHU) Jean-Minjoz, Besançon, France., Bennamoun M; Oncology Department, Institute Mutualiste Montsouris, Paris, France., Hasbini A; Oncology Department, Clinique Pasteur Lanroze, Brest, France., Aldabbagh K; Oncology Department, Polyclinique Saint Côme, Compiègne, France., Saldana C; Oncology Department, Henri Mondor Hospital, Paris Est Créteil University, Therapeutic Resistance in Prostate Cancer, Créteil, France., Sevin E; Oncology Department, Centre Maurice Tubiana, Caen, France., Amela E; Oncology Department, Centre de Cancérologie Les Dentellières, Valenciennes, France., Von Amsberg G; Department of Oncology, Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Houede N; Oncology Department, Institut de Cancérologie du Gard, CHU de Nîmes, Montpellier University, France., Besson D; Oncology Department, Centre Armoricain de Radiothérapie et d'Oncologie, Plérin, France., Feyerabend S; Studienpraxis Urologie, Studienpraxis Urologie, Nürtingen, Germany., Boegemann M; Urology Department, Universitätsklinikum Münster, University Hospital Münster, Münster, Germany., Pfister D; Department of Urology, Uro-Oncology and Robot-Assisted Surgery, University Hospital of Cologne, Cologne, Germany., Schostak M; Department of Urology, Uro-Oncology and Robot-Assisted and Focal Therapy, University Hospital Magdeburg, Otto von Guericke University Magdeburg, Magdeburg, Germany., Huillard O; Oncology Department, Cochin Hospital, AP-HP, Paris, France., Di Fiore F; Uro-Digestive Oncology Unit, Rouen University Hospital, Rouen, France., Quivy A; Oncology Department, Saint André Hospital, Bordeaux, France., Lange C; Uro-Oncologic Health Centre, Bernburg, Germany., Phan L; Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, Paris, France., Belhouari H; Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, Paris, France., Tran Y; Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, Paris, France., Kotti S; Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, Paris, France., Helissey C; Oncology Department, Military Hospital Begin, Saint-Mandé, France.

المصدر: JAMA oncology [JAMA Oncol] 2023 Dec 01; Vol. 9 (12), pp. 1629-1638.

نوع المنشور: Journal Article; Comment

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , Neutropenia*/chemically induced, Male ; Humans ; Aged ; Prospective Studies ; Treatment Outcome ; Taxoids/administration & dosage ; Prednisolone/administration & dosage ; Prednisolone/adverse effects ; Granulocyte Colony-Stimulating Factor/adverse effects

المؤلفون: McHugh DJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Scher HI; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York.

المصدر: JAMA oncology [JAMA Oncol] 2023 May 01; Vol. 9 (5), pp. 617-619.

نوع المنشور: Editorial; Comment

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/pathology , Prostatic Neoplasms, Castration-Resistant*/pathology, Male ; Humans ; Hormones ; Androgen Antagonists

المؤلفون: Yap TA; The University of Texas MD Anderson Cancer Center, Houston., Bardia A; Massachusetts General Hospital, Boston., Dvorkin M; Clinical Oncology Dispensary, Budget Healthcare Institution of Omsk Region, Omsk, Russian Federation., Galsky MD; Icahn School of Medicine at Mount Sinai, New York, New York., Beck JT; Highlands Oncology Group, Springdale, Arkansas., Wise DR; NYU Laura and Isaac Perlmutter Cancer Center, New York, New York., Karyakin O; Medical Radiological Research Center, Kaluga, Russian Federation., Rubovszky G; National Institute of Oncology, Budapest, Hungary., Kislov N; Yaroslavl Regional Cancer Hospital, Yaroslavl, Russian Federation., Rohrberg K; Department of Oncology, Phase I Unit, Rigshospitalet, Copenhagen, Denmark., Joy AA; Cross Cancer Institute, Department of Oncology, University of Alberta, Edmonton, Canada., Telli ML; Stanford University School of Medicine, Stanford, California., Schram AM; Memorial Sloan Kettering Cancer Center, New York, New York., Conte U; Pfizer, New York, New York., Chappey C; Pfizer, San Francisco, California., Stewart R; Now with Translational Medicine, Oncology at AstraZeneca, Cambridge, United Kingdom.; Pfizer, San Diego, California., Stypinski D; Pfizer, San Diego, California., Michelon E; Pfizer, New York, New York., Cesari R; Pfizer, Milan, Italy., Konstantinopoulos PA; Dana-Farber Cancer Institute, Boston, Massachusetts.

المصدر: JAMA oncology [JAMA Oncol] 2023 Jan 01; Vol. 9 (1), pp. 40-50.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Triple Negative Breast Neoplasms*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Lung Neoplasms*/drug therapy , Antineoplastic Agents*/therapeutic use, Male ; Humans ; Middle Aged ; Female ; Poly(ADP-ribose) Polymerase Inhibitors/adverse effects ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/administration & dosage ; Prospective Studies ; Immunotherapy

المؤلفون: Shore ND; Carolina Urologic Research Center, Myrtle Beach, South Carolina., Renzulli J; Yale University, New Haven, Connecticut., Fleshner NE; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Hollowell CMP; Cook County Health, Chicago, Illinois., Vourganti S; Rush University Medical Center, Chicago, Illinois., Silberstein J; Memorial Healthcare System, Hollywood, Florida., Siddiqui R; Astellas Pharma Inc, Northbrook, Illinois., Hairston J; Astellas Pharma Inc, Northbrook, Illinois., Elsouda D; Astellas Pharma Inc, Northbrook, Illinois., Russell D; Pfizer Inc, New York, New York., Cooperberg MR; University of California, San Francisco., Tomlins SA; Departments of Pathology and Urology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor.

المصدر: JAMA oncology [JAMA Oncol] 2022 Aug 01; Vol. 8 (8), pp. 1128-1136.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/pathology , Prostatic Neoplasms, Castration-Resistant*/drug therapy, Aged ; Benzamides/pharmacology ; Benzamides/therapeutic use ; Canada ; Humans ; Male ; Middle Aged ; Nitriles/pharmacology ; Nitriles/therapeutic use ; Phenylthiohydantoin/pharmacology ; Phenylthiohydantoin/therapeutic use ; Prostate-Specific Antigen ; Treatment Outcome ; Watchful Waiting

المؤلفون: Vogelzang NJ; Comprehensive Cancer Centers of Nevada, Las Vegas.; US Oncology Research, The Woodlands, Texas., Beer TM; Oregon Health & Science University, Portland., Gerritsen W; Radboud UMC, Nijmegen, the Netherlands., Oudard S; Georges Pompidou European Hospital, University of Paris, Paris, France., Wiechno P; Oncology Center-Institute Marii Sklodowskiej-Curie, Warszawa, Poland., Kukielka-Budny B; Center of Oncology of the Lublin Region St Jana z Dukli, Lublin, Poland., Samal V; Regional Hospital Liberec, Liberec, Czechia.; Faculty of Medicine in Hradec Kralove, Charles University, Czechia., Hajek J; University Hospital Ostrava, Ostrava, Czechia., Feyerabend S; Studienpraxis Urologie, Nuertingen, Germany., Khoo V; Royal Marsden NHS Foundation Trust, Sutton, United Kingdom., Stenzl A; University Clinic of Urology, Tuebingen, Germany., Csöszi T; Geza Hetenyi Hospital in Szolnok, Szolnok, Hungary., Filipovic Z; University Hospital Medical Center Bezanijska Kosa, Belgrade, Serbia., Goncalves F; CUIMED, Bratislava, Slovakia., Prokhorov A; Minsk City Oncological Dispensary, Minsk, Belarus., Cheung E; Oncology Institute of Hope and Innovation, Long Beach, California., Hussain A; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland., Sousa N; Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal., Bahl A; Bristol Haematology and Oncology Centre, Bristol, United Kingdom., Hussain S; University of Sheffield, Sheffield, United Kingdom., Fricke H; SOTIO a.s., Prague, Czechia., Kadlecova P; SOTIO a.s., Prague, Czechia., Scheiner T; SOTIO a.s., Prague, Czechia., Korolkiewicz RP; SOTIO a.s., Prague, Czechia., Bartunkova J; SOTIO a.s., Prague, Czechia., Spisek R; SOTIO a.s., Prague, Czechia.

مؤلفون مشاركون: VIABLE Investigators

المصدر: JAMA oncology [JAMA Oncol] 2022 Apr 01; Vol. 8 (4), pp. 546-552.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy, Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dendritic Cells/pathology ; Docetaxel/adverse effects ; Double-Blind Method ; Female ; Humans ; Immunotherapy/adverse effects ; Male ; Prednisone

المؤلفون: Aggarwal R; Department of Human Oncology, University of Wisconsin, Madison.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco., Rydzewski NR; Department of Human Oncology, University of Wisconsin, Madison., Zhang L; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.; Division of Hematology and Oncology, University of California, San Francisco., Foye A; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.; Division of Hematology and Oncology, University of California, San Francisco., Kim W; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.; Division of Hematology and Oncology, University of California, San Francisco., Helzer KT; Department of Human Oncology, University of Wisconsin, Madison., Bakhtiar H; Department of Human Oncology, University of Wisconsin, Madison., Chang SL; Department of Radiation Oncology, University of California, San Francisco., Perry MD; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.; Department of Radiation Oncology, University of California, San Francisco., Gleave M; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Reiter RE; Jonsson Comprehensive Cancer Center, Departments of Medicine and Urology, University of California Los Angeles., Huang J; Department of Pathology, Duke University, Durham, North Carolina., Evans CP; Comprehensive Cancer Center, Department of Urologic Surgery, University of California Davis, Sacramento., Alumkal JJ; Department of Internal Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor., Lang JM; Department of Medicine, University of Wisconsin, Madison., Yu M; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison., Quigley DA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.; Department of Epidemiology and Biostatistics, University of California, San Francisco., Sjöström M; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.; Department of Radiation Oncology, University of California, San Francisco., Small EJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.; Division of Hematology and Oncology, University of California, San Francisco., Feng FY; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.; Division of Hematology and Oncology, University of California, San Francisco.; Department of Radiation Oncology, University of California, San Francisco.; Department of Urology, University of California, San Francisco., Zhao SG; Department of Human Oncology, University of Wisconsin, Madison.; William S. Middleton Memorial Veterans Hospital, Madison.

المصدر: JAMA oncology [JAMA Oncol] 2021 Nov 01; Vol. 7 (11), pp. 1644-1652.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/pathology, Cohort Studies ; Humans ; Male ; Prognosis ; Prospective Studies ; Retrospective Studies

المؤلفون: Yang DD; Harvard Radiation Oncology Program, Boston, Massachusetts., Mahal BA; Department of Radiation Oncology, University of Miami, Miami, Florida., Pike LRG; Department of Radiation Oncology, Memorial Sloan Kettering Cancer, New York, New York.

المصدر: JAMA oncology [JAMA Oncol] 2021 Jul 01; Vol. 7 (7), pp. 1014-1015.

نوع المنشور: Journal Article; Comment

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/pathology , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology, Biomarkers ; Humans ; Male

المؤلفون: Feng FY; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco., Thomas S; Janssen Research & Development, Spring House, Pennsylvania., Saad F; Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada., Gormley M; Janssen Research & Development, Spring House, Pennsylvania., Yu MK; Janssen Research & Development, Los Angeles, California., Ricci DS; Janssen Research & Development, Spring House, Pennsylvania., Rooney B; Janssen Research & Development, High Wycombe, United Kingdom., Brookman-May S; Janssen Research & Development, Los Angeles, California., McCarthy S; Janssen Research & Development, Raritan, New Jersey., Olmos D; Spanish National Cancer Research Centre, Madrid, Spain.; Institituto de Investigación Biomédica de Málaga, Málaga, Spain., Chowdhury S; Guy's, King's and St. Thomas' Hospitals, Great Maze Pond, London, United Kingdom., Hadaschik B; West German Cancer Center, Department of Urology, University of Duisburg-Essen, Essen, Germany.; Department of Urology, University Hospital Heidelberg, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany., Liu Y; Decipher Biosciences Inc, San Diego, California., Davicioni E; Decipher Biosciences Inc, San Diego, California., Smith MR; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Small EJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco.

المصدر: JAMA oncology [JAMA Oncol] 2021 Jul 01; Vol. 7 (7), pp. 1005-1014.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/genetics, Aged ; Aged, 80 and over ; Androgen Antagonists/adverse effects ; Androgen Receptor Antagonists ; Cohort Studies ; Humans ; Male ; Middle Aged ; Thiohydantoins ; Treatment Outcome

المؤلفون: Wang L; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.; Center for Drug Safety and Effectiveness, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland., Paller CJ; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Hong H; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.; Duke Clinical Research Institute, Duke University, Durham, North Carolina., De Felice A; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland., Alexander GC; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.; Center for Drug Safety and Effectiveness, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland., Brawley O; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

المصدر: JAMA oncology [JAMA Oncol] 2021 Mar 01; Vol. 7 (3), pp. 412-420.

نوع المنشور: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Prostatic Neoplasms*/pathology , Prostatic Neoplasms, Castration-Resistant*/pathology, Androgen Antagonists/adverse effects ; Bayes Theorem ; Castration ; Humans ; Male ; Network Meta-Analysis ; Treatment Outcome